624 related articles for article (PubMed ID: 12515720)
1. Downstream effectors of oncogenic ras in multiple myeloma cells.
Hu L; Shi Y; Hsu JH; Gera J; Van Ness B; Lichtenstein A
Blood; 2003 Apr; 101(8):3126-35. PubMed ID: 12515720
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
[TBL] [Abstract][Full Text] [Related]
3. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.
Shi Y; Hsu JH; Hu L; Gera J; Lichtenstein A
J Biol Chem; 2002 May; 277(18):15712-20. PubMed ID: 11872747
[TBL] [Abstract][Full Text] [Related]
4. Ras-mediated up-regulation of survivin expression in cytokine-dependent murine pro-B lymphocytic cells.
Shinjyo T; Kurosawa H; Miyagi J; Ohama K; Masuda M; Nagasaki A; Matsui H; Inaba T; Furukawa Y; Takasu N
Tohoku J Exp Med; 2008 Sep; 216(1):25-34. PubMed ID: 18719335
[TBL] [Abstract][Full Text] [Related]
5. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
6. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
[TBL] [Abstract][Full Text] [Related]
7. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway.
Sulpice E; Bryckaert M; Lacour J; Contreres JO; Tobelem G
Blood; 2002 Nov; 100(9):3087-94. PubMed ID: 12384403
[TBL] [Abstract][Full Text] [Related]
8. Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2).
Zhang B; Fenton RG
J Cell Physiol; 2002 Oct; 193(1):42-54. PubMed ID: 12209879
[TBL] [Abstract][Full Text] [Related]
9. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling.
Zhang D; Brodt P
Oncogene; 2003 Feb; 22(7):974-82. PubMed ID: 12592384
[TBL] [Abstract][Full Text] [Related]
10. Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways.
Campbell M; Allen WE; Sawyer C; Vanhaesebroeck B; Trimble ER
Circ Res; 2004 Aug; 95(4):380-8. PubMed ID: 15242975
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
[TBL] [Abstract][Full Text] [Related]
12. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway.
Birkenkamp KU; Geugien M; Schepers H; Westra J; Lemmink HH; Vellenga E
Leukemia; 2004 Jan; 18(1):103-12. PubMed ID: 14574326
[TBL] [Abstract][Full Text] [Related]
13. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.
Banerji L; Glassford J; Lea NC; Thomas NS; Klaus GG; Lam EW
Oncogene; 2001 Nov; 20(50):7352-67. PubMed ID: 11704865
[TBL] [Abstract][Full Text] [Related]
14. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
Chatterjee M; Hönemann D; Lentzsch S; Bommert K; Sers C; Herrmann P; Mathas S; Dörken B; Bargou RC
Blood; 2002 Nov; 100(9):3311-8. PubMed ID: 12384432
[TBL] [Abstract][Full Text] [Related]
15. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 activates phosphoinositol-3' kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways.
Hsu JH; Shi Y; Frost P; Yan H; Hoang B; Sharma S; Gera J; Lichtenstein A
Oncogene; 2004 Apr; 23(19):3368-75. PubMed ID: 15021914
[TBL] [Abstract][Full Text] [Related]
17. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.
Ogata A; Chauhan D; Teoh G; Treon SP; Urashima M; Schlossman RL; Anderson KC
J Immunol; 1997 Sep; 159(5):2212-21. PubMed ID: 9278309
[TBL] [Abstract][Full Text] [Related]
18. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells.
Kawauchi K; Ihjima K; Yamada O
J Immunol; 2005 May; 174(9):5261-9. PubMed ID: 15843522
[TBL] [Abstract][Full Text] [Related]
19. Activated Ki-Ras suppresses 12-O-tetradecanoylphorbol-13-acetate-induced activation of the c-Jun NH2-terminal kinase pathway in human colon cancer cells.
Okumura K; Shirasawa S; Nishioka M; Sasazuki T
Cancer Res; 1999 May; 59(10):2445-50. PubMed ID: 10344756
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM
Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
